The effect of acetyl salicylic acid and dipyridamole on thromboembolic complications in splenectomized patients with myelofibrosis.
The effect of combined treatment with acetyl salicylic acid and dipyridamole on thrombic phenomena was studied in splenectomized patients with an aggressive form of myelofibrosis. 3 of these patients had thrombotic episodes, shortened platelet survival and an abnormal platelet aggregation pattern. The treatment with antiplatelet drugs resulted in a decreased platelet utilization as evidenced by clinical improvement and an increasing platelet concentration.
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D001792:Blood Platelets; D002470:Cell Survival / Q000187:drug effects; D004176:Dipyridamole / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013156:Splenectomy; D013923:Thromboembolism / Q000150:complications / Q000188:drug therapy*
D004176:Dipyridamole; D010960:Plasminogen Activators; D001241:Aspirin